Next Article in Journal
Is It Meanwhile Biomedical Sciences or Still “Ars Medica”?
Previous Article in Journal
ER-to-Golgi Transport in HeLa Cells Displays High Resilience to Ca2+ and Energy Stresses
Open AccessArticle

Anti-Müllerian Hormone Type II Receptor Expression in Endometrial Cancer Tissue

1
Department of Gynecology and Obstetrics, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
2
Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
3
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368Wroclaw, Poland
4
Department of Pathomorphology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland
5
Department of Ecology & Environmental Protection, University of Warmia and Mazury in Olsztyn, 10-727 Olsztyn, Poland
6
Department of Physiotherapy, Wroclaw University School of Physical Education, 51-612 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
Cells 2020, 9(10), 2312; https://doi.org/10.3390/cells9102312
Received: 24 August 2020 / Revised: 8 October 2020 / Accepted: 15 October 2020 / Published: 17 October 2020
(This article belongs to the Section Cellular Pathology)
Anti-Müllerian hormone (AMH) is responsible for the Müllerian ducts’ regression in male fetuses. In cells of cancers with AMH receptors (AMHRII), AMH induces cell cycle arrest or apoptosis. As AMH occurs naturally and does not exhibit significant side effects while reducing neoplastic cell colonies, it can be considered as a potential therapeutic agent for cancer treatment. The purpose of this study was to assess the AMHRII expression in endometrial cancer (EC) in correlation to various demographic data and clinical conditions. Immunohistochemical analysis was used to assess AMHRII expression in EC tissue samples retrieved from 230 women with pre-cancerous state of endometrium (PCS) and EC. AMHRII was detected in 100% of samples. No statistical difference was observed for AMHRII expression depending on the histopathological type of EC, cancer staging, body mass index, and age, as well as the number of years of menstruation, births and miscarriages, and average and total breastfeeding time. Diabetes mellitus type 2 is the only factor that has an impact on AMHRII expression in EC tissue. Thus, this study supports the idea of theoretical use of AMH in EC treatment because all histopathological types of EC at all stages of advancement present receptors for AMH. View Full-Text
Keywords: endometrial cancer; AMHRII; AMH; expression; tissue microarray endometrial cancer; AMHRII; AMH; expression; tissue microarray
Show Figures

Figure 1

MDPI and ACS Style

Gowkielewicz, M.; Lipka, A.; Majewska, M.; Piotrowska, A.; Szadurska-Noga, M.; Nowakowski, J.J.; Wiszpolska, M.; Dzięgiel, P.; Wasniewski, T.; Majewski, M.K.; Jozwik, M. Anti-Müllerian Hormone Type II Receptor Expression in Endometrial Cancer Tissue. Cells 2020, 9, 2312.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop